Background {#Sec1}
==========

Splenosis is the heterotopic autotransplantation of splenic tissue throughout the peritoneal and pelvic cavities, even the thoracic cavity, following splenic trauma or elective splenectomy \[[@CR1]\]. The splenic fragments usually seed onto exposed vascularized peritoneal surface, receiving blood supply from the surrounding tissue. Intrahepatic splenosis is quite rare, as the majority of splenosis reported in the English literature was found to be located in the mesentery, omentum, and peritoneum \[[@CR2]\]. The lack of typical radiological features makes it difficult to distinguish splenosis from liver tumors and reach a correct diagnosis. Herein, we present a case of isolated intrahepatic splenosis and summarize the relevant radiological and pathological characteristics. On the basis of literature review, imaging techniques that may contribute to the diagnosis and appropriate treatment measures are also discussed.

Case presentation {#Sec2}
=================

A 54-year-old Chinese male was referred to our hospital for further evaluation of a liver mass, which was discovered incidentally during routine physical examination in a local hospital. The patient had a 10-year history of hypertension and was diagnosed with diabetes mellitus approximately 5 years before. He denied history of liver cirrhosis and hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. The patient underwent splenectomy 5 years earlier owing to a high-altitude falling accident. No mass was identifiable on abdominal palpation exam. Serum tumor markers (alpha-fetoprotein, CA199, and CA125) were within the normal range. Abdominal ultrasonography (US) revealed a 5 cm iso-echoic lesion that located in the left hepatic lobe near the capsule. A 1.2 cm gallstone was also observed. An abdominal plane-computed tomography (CT) scan revealed an oval, slightly hypodense mass located in segment IV of the left liver lobe measuring 4.5 × 3.3 cm. The lesion had an inhomogeneous enhancement during the arterial phase and diminished enhancement during the portal and equilibrium phases on a contrast-enhanced CT scan (Fig. [1](#Fig1){ref-type="fig"}). Abdominal magnetic resonance imaging (MRI) showed a slightly hypointense mass on both T1- and T2-weighted images, which appeared slightly hyperintense on diffusion-weighted images. After the injection of gadoxetic acid, the lesion appeared strongly heterogeneous and hyperintense during the arterial phase and relatively hypointense during the portal and equilibrium phases (Fig. [2](#Fig2){ref-type="fig"}). An indication of a pseudo-capsule was also observed. Partial hepatectomy and cholecystectomy were performed with the suspicion of hepatocellular carcinoma (HCC).Fig. 1Contrast-enhanced computed tomography scan of intrahepatic splenosis. The lesion had an inhomogeneous enhancement during the arterial phase (**a**) and diminished enhancement during the portal phase (**b**) and equilibrium phase(**c**)Fig. 2Magnetic resonance imaging scan of intrahepatic splenosis. Note a slightly hypointense mass on both T1-weighted (**a**) and T2-weighted (**b**) images. After the injection of gadoxetic acid, the mass became strongly heterogeneous and hyperintense during the arterial phase (**c**) and relatively hypointense during the portal phase (**d**)

During the operation, the intrahepatic mass was found to be located in segment IV of the liver, measuring 4.0 cm in diameter. It was completely embedded in the liver tissue, and no other mass was found. Postoperative hematoxylin and eosin staining revealed sinusoidal structures and lymphoid tissue hyperplasia. A capsule separating the spleen tissue from liver tissue could be clearly detected (Fig. [3](#Fig3){ref-type="fig"}), which confirmed intrahepatic splenosis. Detailed immunohistochemical staining showed positivity for CD3 and CD20, specific markers for lymphocyte T cells and B cells, respectively. Meanwhile, the expression of the Ki-67 antigen was quite limited. The polyclonal nature of the lymphocytes and the low proliferation activity further confirmed the benign characteristic of the mass, as malignant tumors are always monoclonal with active proliferation. The patient discharged uneventfully after the operation, and no symptoms of recurrence have been observed during 2 years of follow-up.Fig. 3Histopathological features of intrahepatic splenosis. Hematoxylin and eosin staining. **a** A capsule clearly separated the liver (white arrow) and spleen (black arrow) parenchyma, × 100. **b** Intrahepatic splenosis with lymphoid tissue hyperplasia and sinusoidal structures, × 400

Literature review {#Sec3}
=================

We searched the PubMed and Scopus databases for relevant English literature from the year 2000 through March 2018 using the Medical Subject Headings (MeSH) "Hepatocellular Carcinoma," "Liver Neoplasm," and "Splenosis." In total, 37 cases of intrahepatic splenosis were identified and reviewed \[[@CR3]--[@CR37]\]. Characteristics of the cases such as age and sex of patients, clinical symptoms, diagnostic modality, and location of the masses were reviewed and analyzed (Table [1](#Tab1){ref-type="table"}). There were 31 (83.8%) male and 6 (16.2%) female patients, and the mean age of the patients was 49.2 years (ranging from 21 to 73 years).Table 1Clinical data of 37 cases of intrahepatic splenosisAuthor, yearAge (years), genderTrauma, splenectomyLiver diseasesTime interval (years)SymptomsDiagnostic modalityNumberSubcapsular locationCapsuleDiagnostic hypothesisSegment, size (mm)Invasive measureFollow-upTeles 2018 \[[@CR3]\]73, MSplenectomyNoN/DLower back painUS, CT, MRI\
scintigraph2YesYeshepatic neoplasiaII, III\
36SurgeryNo symptoms for 2 yearsWang 2017 \[[@CR4]\]54, MBothHBV23Abdominal painUS, CT, MRI1YesYesHCCRight posterior lobe 31 × 27SurgeryNo symptoms for 18 monthsWang 2017 \[[@CR5]\]42, MBothHBV/BCV16Lower back painCT, MRI1YesYesHCCIV\
3 × 3SurgeryN/DKeck 2017 \[[@CR6]\]66, MBothHCVN/DNoMRI2YesN/DHCCVII, VIII\
53BiopsyN/DJereb 2016 \[[@CR7]\]22, MBothNo18NoUS, CT, MRI5YesN/DLiver metastasesII, VI, VII\
26 × 26SurgeryN/DHe 2016 \[[@CR8]\]51, MBothNo20NoUS, CT, MRI2N/DN/DHCCLeft lobe, right lobe 33 × 26BiopsyN/DLiu 2015 \[[@CR9]\]33, MBothNo30NoUS, CT, MRI3YesN/DHCC/Liver metastasesIII, Right lobe\
42 × 30BiopsyNo symptoms for 2 yearsLi 2015 \[[@CR10]\]67, FBothHCV, cirrhosis5NoCT, MRI\
angiography1N/DYesHCCLeft lobeSurgeryNo symptoms for 3 yearsSato 2014 \[[@CR11]\]58, MNeitherHCV, cirrhosisNoNoUS, CT, MRI1YesYesHCCRight lateral lobe 39 × 30SurgeryNo symptoms for 1 yearLevi Sandri 2014 \[[@CR12]\]54, MBothHBV, cirrhosis25N/DCT1N/DYesHCCIII\
45 × 35 × 15SurgeryN/DLeong 2013 \[[@CR13]\]56, MBothNo25Abdominal painUS, CT, MRI\
PET1N/DN/DNeuroendocrine tumorIII\
46 × 37 × 31SurgeryNo symptoms for 6 monthsKrawczyk 2013 \[[@CR14]\]39, FBothNoN/DAbdominal painCT, MRI, scintigraphy1YesN/DHepatocellular adenomaII\
32 × 20NoNo symptoms for 3 monthsInchingolo 2013 \[[@CR15]\]53, MBothNon alcoholic steatohepatitis33NoUS, CT, MRI1YesN/DHCC/hepatic adenomaIII, IV\
35SurgeryN/DLiu 2012 \[[@CR16]\]49, FBothNo20Subxiphoid painUS, CT3YesN/DLiver tumorLeft lateral lobe\
50 × 50SurgeryNo symptoms for 4 monthsLiu 2012 \[[@CR17]\]38, MBothHBV14NoUS, CT1YesYesLiver tumorLeft lateral lobe\
33 × 27SurgeryN/DKang 2011 \[[@CR18]\]54, MBothNo15NoUS, CT, MRI\
PET-CT2YesYesLiver metastatic\
nodulesII\
23 × 19SurgeryN/DMescoli 2010 \[[@CR19]\]68, FNeitherHepatitis, cirrhosisNoAbdominal painUS, CT, MRI3N/DN/DLiver tumorIII, V, VII\
150BiopsyN/DMescoli 2010 \[[@CR19]\]54, MSplenectomyNo12NoCT, PET-CT1N/DNoLiver metastatic\
noduleLeft lobe\
30SurgeryNo symptoms for 8 monthsYu 2009 \[[@CR20]\]54, MBothNo20NoUS, CT, MRI1YesYesN/DLeft lobe\
40SurgeryNo symptoms for 6 monthsMenth 2009 \[[@CR21]\]43, MBothHCV, cirrhosis30FatigueUS, CT, MRI\
angiography, scintigraphyMultipleYesN/DHCCII\
36BiopsyNo symptoms for 9 monthsKashgari\
2009 \[[@CR22]\]52, MBothHCV, cirrhosis30NoUS, MRI1YesN/DHCCVII\
21 × 15BiopsyNo symptoms for 4 monthsAbu Hilal\
2009 \[[@CR23]\]60, MBothHCV, cirrhosis46Flu-like symptomsUS, CT, MRI1YesN/DHCCVII\
30SurgeryNo symptoms for 2 yearsYeh 2008 \[[@CR24]\]64, MBothHCV8NoUS, CT, MRI\
angiography1YesYesHCCVI\
25SurgeryN/DNakajima 2008 \[[@CR25]\]41, MBothN/D21Abdominal pain and diarrheaUS, CT, MRI1YesN/DN/DVI\
N/DBiopsyN/DImbriaco\
2008 \[[@CR26]\]39, MBothNo24Abdominal painUS, CT, MRIMultipleYesN/DLiver metastatic\
nodulesLeft lobe, right lobe 30SurgeryN/DGrande\
2008 \[[@CR27]\]41, MBothNo35NoUS, CT,\
scintigraphyMultipleYesN/DN/DVII\
45NoN/DChoi\
2008 \[[@CR28]\]32, MBothHBV26NoCT, MRI\
angiography3YesYesHCCIVa, IVb, VI\
30SurgeryN/DBrancatelli\
2005 \[[@CR29]\]38, FBothNo32NoCT, MRI\
scintigraphy1YesN/DLiver adenomaLeft lobe\
50BiopsyN/DZhao\
2004 \[[@CR30]\]49, MBothNo17NoUS, CT1YesYesLiver adenoma/HCCVII\
50 × 30 × 30SurgeryNo symptoms for 1 yearKondo\
2004 \[[@CR31]\]55, MBothHCV31NoUS, CT, MRI(SPIO)\
angiography2N/DN/DHCCVII\
35 × 35BiopsyN/DIzzo\
2004 \[[@CR32]\]60, MBothHCV43JaundiceUS, CT, MRI1N/DN/DHCCNear the hilum 60BiopsyN/DDi Costanzo\
2004 \[[@CR33]\]58, MBothHBV, cirrhosis46NoUS, CT,\
scintigraphy1YesN/DHCCIII\
48BiopsyN/DDi Costanzo\
2004 \[[@CR33]\]48, FBothHCV, cirrhosis41NoUS, CT1YesYesHCCIII\
31BiopsyN/DKim\
2003 \[[@CR34]\]43, MBothHBV, cirrhosis21NoUS, CT,\
angiography1YesYesHCCRight lobe\
30SurgeryN/DPekkafali\
2002 \[[@CR35]\]21, MBothNo15Epigastric painUS, CT, MRI\
scintigraphy1YesYesNoLeft lobe\
34 × 23NoN/DLee\
2002 \[[@CR36]\]43, MBothHBV, cirrhosis20FatigueUS, CT, angiography1YesYesHCCVI\
33 × 20SurgeryN/DDe Vuysere\
2000 \[[@CR37]\]50, MBothNo34NoUS, CT, MRI(SPIO)3N/DYesNoLeft lobe, right lobe 60BiopsyN/D*HBV* hepatitis B virus, *HCV* hepatitis C virus, *HCC* hepatocellular carcinoma, *US* ultrasonography, *CT* computed tomography, *MRI* magnetic resonance imaging, *PET* positron emission tomography, *M* male, *F* female, *N/D* not disclosed^a^Time interval: time elapsing between trauma/splenectomy and diagnosis of intrahepatic splenosis^b^When multiple lesions, only the size of the largest one was presented^c^Surgery: included laparoscopic resection and laparotomy

In the 37 documented cases, 35 (94.6%) patients had histories of trauma or/and splenectomy, and the mean time elapsing between trauma/splenectomy and diagnosis of intrahepatic splenosis was 24.9 years (ranging from 5 to 46 years). A total of 20 (54.1%) patients had related liver diseases, among which 8 (40%) had HBV infection, 11 (55%) had HCV infection, and 11 (55%) had cirrhosis. Most of the patients were asymptomatic upon admission, except for 6 (16.2%) who had abdominal pain. US, CT, and MRI were common imaging techniques, but they did not clearly differentiate intrahepatic splenosis from other liver lesions, such as HCC, liver metastases, or liver adenoma. Scintigraphy was used in 7 (18.9%) patients, and in 3 (42.9%) of them, the imaging led to the correct diagnosis without further invasive measures. The majority of intrahepatic splenosis were located in the subcapsular region of the liver, surrounded by capsules. A total of 34 (91.9%) patients had undergone invasive procedures. Surgery in 21 (61.8%) patients, including laparoscopic resection and laparotomy, was the most common invasive procedure followed by biopsy in 13 (38.2%).

Discussion {#Sec4}
==========

Splenosis represents the heterotopic autotransplantation and implantation of splenic tissue after elective splenectomy or traumatic spleen rupture. Once considered to be a rare condition, a recent estimated incidence is up to 67% of patients who have a history of splenic rupture or surgery \[[@CR38]\]. Intrahepatic splenosis is still rare, as most of the splenoses were located in the mesentery, omentum, or peritoneum. Except for some extraordinary cases, almost all of the cases with intrahepatic splenosis have a history of splenic trauma or splenectomy \[[@CR11], [@CR19]\]. Hence, intrahepatic splenosis should be taken into consideration in patients with a relevant history, especially if the mass is found to be located close to the liver capsule.

The absence of typical radiological features makes it difficult to reach a correct diagnose with common imaging techniques, such as US, CT, and MRI. As a result, intrahepatic splenosis can be confused with HCC, adenoma, or other liver diseases, leading to unnecessary surgery or other invasive treatments. Therefore, more sensitive novel methods to diagnose intrahepatic splenosis are needed. Scintigraphy with sensitive technetium-99 m-labeled heat-denatured red blood cells (Tc-99 m-DRBC) is reported to be the most specific and efficient diagnostic method \[[@CR20]\]. As approximately 90% of damaged erythrocytes will be trapped by splenic tissue, remarkable differences in uptake of the radioactive isotope can be observed between intrahepatic splenic tissue and normal liver tissue. Krawczyk et al. \[[@CR14]\], Grande et al. \[[@CR27]\], and Pekkafali et al. \[[@CR35]\] reported three cases that successfully avoided invasive treatments by using Tc-99 m-DRBC scintigraphy. Scintigraphy with sulfur colloid is considered to be another useful diagnostic method, but has a lower sensitivity in identification of splenosis \[[@CR39]\]. Superparamagnetic iron oxide (SPIO) contrast magnetic resonance imaging may be helpful for the diagnosis of splenosis. As reported, intrahepatic splenosis will remain hyperintense relative to the liver parenchyma, while HCC will become hypointense after the SPIO administration \[[@CR37]\].

In fact, most of the cases with intrahepatic splenosis that had been reported were treated with invasive procedures, including biopsy and surgical resection. However, intrahepatic splenosis may be beneficial in the patients who have undergone splenectomy, since it can replace part of the immunologic function of the removed spleen \[[@CR40]\]. Hence, conservative treatment is strongly recommended for asymptomatic intrahepatic splenosis, except for some special situations, such as idiopathic thrombocytopenic purpura and Felty syndrome.

In order to avoid unnecessary invasive treatment, accurate diagnosis is essential. Although some novel imaging methods, such as scintigraphy, have shown promising application prospects in diagnosis of intrahepatic splenosis, they will not likely be used worldwide for quite some time. Instead, we think it may be helpful to use a scoring system to evaluate the suspicious degree of intrahepatic mass to be splenosis (Table [2](#Tab2){ref-type="table"}). Compared with the CT/MRI Li-Rads v2017 \[[@CR41]\], our scoring system seems to be more effective in diagnosing intrahepatic splenosis. The major imaging features (washout, enhancing "capsule" and threshold growth) of Li-Rads were not enough to distinguish intrahepatic splenosis from liver neoplasm. According to the table, the higher the total score is, the stronger is the possibility that the mass will be splenosis. When the total score is greater than 3, it is better to use biopsy to clarify the diagnosis, instead of taking more aggressive measures directly.Table 2Suspicious degree of intrahepatic mass to be splenosisParametersScoreMethods01Alpha-fetoprotein\> 400 μg/L for 4 weeks\
\> 200 μg/L for 8 weeksNoELISACirrhosisYesNoUS, CT, MRIHepatitisYesNoELISA, PCRSplenic traumaNoYesHistory taking/\
US, CT, MRISplenectomyNoYesHistory taking/\
US, CT, MRIMass locationNon-subcapsularsubcapsularUS, CT, MRIMass capsuleNoYesUS, CT, MRIHowell-Jolly and Heinz bodies after splenectomyYesNoHematological examination*ELISA* enzyme-linked immunosorbent assay, *US* ultrasonography, *CT* computed tomography, *MRI* magnetic resonance imaging, *PCR* polymerase chain reaction^a^For alpha-fetoprotein, exclude pregnancy, acute severe hepatitis, embryonic gonad tumors, and other digestive system tumor

Conclusion {#Sec5}
==========

Although isolated intrahepatic splenosis is rarely encountered, it should be taken into account in the differential diagnosis of a liver lesion, especially if the patient has a history of splenic trauma or splenectomy. The proposed scoring system may be useful in diagnosing intrahepatic splenosis when effective diagnostic methods, like scintigraphy and SPIO MRI, are lacking. If intrahepatic splenosis has been confirmed, conservative treatment is strongly recommended for the patient without any symptoms.
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